Philips expands network of clinical partners to set new standard of care for the early diagnosis and treatment of lung cancer
28 März 2022 - 11:00AM
Philips expands network of clinical partners to set new standard of
care for the early diagnosis and treatment of lung cancer
March 28, 2022
- New installs of Philips Lung Suite real-time 3D imaging
solution in Belgium, France, Israel, and the UK highlight
rapidly-growing global clinical interest in the company’s
integrated all-in-one lung cancer diagnosis and treatment imaging
solution
- Solution supports precision diagnosis and minimally-invasive
therapy in one room
- Clinical trials for minimally invasive therapy procedures using
advanced imaging from Philips Lung Suite start with successful
first cases
Amsterdam, the Netherlands - Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
provided an update on the growing global clinical interest in its
innovative lung cancer diagnosis and treatment solution – Philips
Lung Suite – which is underlined by its rapid roll-out with new
clinical partners. Some of the new innovating partner sites are:
Royal Brompton Hospital – London UK; Hôpital Erasme – Brussels,
Belgium; Ziekenhuis Oost-Limburg (ZOL), Genk Medical Center – Genk,
Belgium; Carmel Medical Center – Haifa, Israel. Rouen University
Hospital – Rouen, France is also planning to start using the
innovation. Several healthcare providers have already successfully
diagnosed their first patients using Lung Suite, which works in
combination with the company’s Image Guided Therapy System –
Azurion.
Lung cancer is the number one cause of cancer death worldwide,
claiming the lives of 1.8 million people per year [1]. More than
60% of lung cancer patients are diagnosed at a late stage, reducing
their odds of survival [2]. Philips Lung Suite is a revolutionary
3D real-time imaging platform that addresses the need for earlier
precision diagnosis and minimally-invasive treatment with an
all-in-one platform that enables doctors to perform biopsy,
ablation, marking of lesions, and/or thoracic surgery procedures in
the same room, allowing patients to be both diagnosed and treated.
Its ability to locate and characterize small-sized lesions could
significantly enhance future lung cancer care.
“Philips Lung Suite has been shown to increase the accuracy of
lung cancer biopsy procedures, improving results for patients and
offering the potential to immediately treat early-stage lung cancer
patients,” said Karim Boussebaa, General Manager, Image Guided
Therapy Systems at Philips. “These new partners add to our rapidly
expanding global ecosystem of clinical partners who are pushing
innovation forward, with of the goal of offering patients diagnosis
and minimally-invasive treatment in a single procedure, improving
patient outcomes and their quality of life.”
No nodule can hidePhilips Lung Suite provides
advanced real-time 3D imaging with augmented fluoroscopy on the
company’s Image Guided Therapy Systems – such as Azurion, combined
with dedicated software. With Philips’ Cone Beam CT imaging, the
X-ray detector rotates around the patient to generate a CT-like
image in around five seconds, providing clinicians with a
high-resolution 3D view of the target lesion and other anatomical
structures. This allows the clinician performing the biopsy
procedure to be continually guided by high-quality real-time
imaging to advance a catheter towards the lesion through a
bronchoscope. Once done, its position can be confirmed in real-time
using the same imaging modality, and a biopsy sample can be
taken.
“In the fast-growing world of intraoperative imaging,
cone-beam CT remains the gold standard for augmented fluoroscopy
and lesion confirmation. Using Lung Suite, no nodule can hide,
regardless of anatomical position or radiologic
characteristic, making it a valuable tool for both diagnosis and
future ablation procedures,” said Dr. Amir Abramovich, MD.,
Director of Interventional Pulmonology at the Carmel Medical Center
in Haifa, Israel.
“Cone-beam CT is the critical step towards targeting sub-20 mm
nodules and an essential tool for the transition towards
bronchoscopic microwave ablation of peripheral lung lesions,” said
Professor Shah Pallav, MD., consultant respiratory physician at
Royal Brompton Hospital in London, UK.
“The advanced cone beam CT imaging combined with augmented
fluoroscopy of Philips Lung Suite gives us the confidence to safely
reach and biopsy difficult-to-access peripheral lung nodules,” said
Maarten Criel, MD., Pulmonologist at ZOL Genk Medical Center,
Belgium.
Dr. Kelvin Lau, consultant and lead thoracic surgeon at St
Bartholomew’s Hospital, London, successfully diagnosed and treated
lung cancer patients using cone beam CT for biopsy, bronchoscopic
microwave ablation and for precision image-guided surgery, all in
one procedure, during initial clinical trial. Advanced imaging with
Philips Lung suite is used during procedures for real-time 3D image
guidance and confirmation. Additional clinical trials at various
hospitals are expected to start soon.
An October 2021 paper in the Journal of Bronchology &
Interventional Pulmonology authored by researchers at Radboud
University Medical Center, the Netherlands, demonstrated the
diagnostic potential of Lung Suite. The researchers were able to
raise the diagnostic accuracy of navigation bronchoscopy from 72%
to 90%. In addition, the average total effective radiation dose per
procedure was reduced by more than half [3].
[1] https://www.who.int/news-room/fact-sheets/detail/cancer[2]
https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html[3]
Journal of Bronchology & Interventional Pulmonology: October
2021 - Volume 28 - Issue 4 - p 262-271 doi:
10.1097/LBR.0000000000000783
For further information, please contact:
Joost Maltha Philips Global Press Office Tel:
+31 6 10 55
8116 E-mail: joost.maltha@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail: fabienne.van.der.feer@philips.com
About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and well-being, and enabling better outcomes across
the health continuum – from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company
is a leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Philips Lung Suite - 01
- Philips Lung Suite - 02
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Koninklijke Philips NV (BIT:1PHIA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024